CARDIFF ONCOLOGY, INC. Lease, Cost
CARDIFF ONCOLOGY, INC. (CRDF) reported Lease, Cost of $667.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-02-27
- CARDIFF ONCOLOGY, INC. lease, cost for the quarter ending 2023-03-31 was $183.00K, a 4.19% decline year-over-year.
- CARDIFF ONCOLOGY, INC. lease, cost for the quarter ending 2022-12-31 was $186.00K, a 5.08% increase year-over-year.
- CARDIFF ONCOLOGY, INC. lease, cost for the quarter ending 2022-09-30 was $188.00K, a 4.44% increase year-over-year.
- CARDIFF ONCOLOGY, INC. lease, cost for the quarter ending 2022-06-30 was $190.00K.
- CARDIFF ONCOLOGY, INC. lease, cost for fiscal 2024 was $667.00K, a 6.58% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. lease, cost for fiscal 2023 was $714.00K, a 5.31% decline from fiscal 2022.
- CARDIFF ONCOLOGY, INC. lease, cost for fiscal 2022 was $754.00K, a 120.47% increase from fiscal 2021.
- CARDIFF ONCOLOGY, INC. lease, cost for fiscal 2021 was $342.00K, a 128.00% increase from fiscal 2020.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $667.00K 10-K · filed 2025-02-27 | |||||||
| 2023-12-31 | $714.00K 10-K · filed 2025-02-27 | |||||||
| 2023-03-31 | $183.00K 10-Q · filed 2023-05-04 | $369.00K derived: sum of 2 quarters · filed 2024-02-29 | $557.00K derived: sum of 3 quarters · filed 2024-02-29 | $747.00K derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $374.00K derived: sum of 2 quarters · filed 2024-02-29 | $564.00K derived: sum of 3 quarters · filed 2024-02-29 | $754.00K 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $188.00K 10-Q · filed 2022-11-03 | $378.00K derived: sum of 2 quarters · filed 2022-11-03 | $568.00K 10-Q · filed 2022-11-03 | $746.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-06-30 | $190.00K 10-Q · filed 2022-08-04 | $381.00K 10-Q · filed 2022-08-04 | $558.00K derived: sum of 3 quarters · filed 2023-05-04 | $738.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-03-31 | $191.00K 10-Q · filed 2023-05-04 | $368.00K derived: sum of 2 quarters · filed 2023-05-04 | $548.00K derived: sum of 3 quarters · filed 2023-05-04 | $539.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $357.00K derived: sum of 2 quarters · filed 2023-03-02 | $348.00K derived: sum of 3 quarters · filed 2023-03-02 | $342.00K 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | $180.00K 10-Q · filed 2022-11-03 | $171.00K derived: sum of 2 quarters · filed 2022-11-03 | $165.00K 10-Q · filed 2022-11-03 | $188.00K derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$9.00K 10-Q · filed 2022-08-04 | -$15.00K 10-Q · filed 2022-08-04 | $8.00K derived: sum of 3 quarters · filed 2022-08-04 | $34.00K derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$6.00K 10-Q · filed 2022-05-05 | $17.00K derived: sum of 2 quarters · filed 2022-05-05 | $43.00K derived: sum of 3 quarters · filed 2022-05-05 | $109.00K derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $49.00K derived: sum of 2 quarters · filed 2022-02-24 | $115.00K derived: sum of 3 quarters · filed 2022-02-24 | $150.00K 10-K · filed 2022-02-24 | $150.36K 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $26.00K 10-Q · filed 2021-11-04 | $26.02K 10-Q · filed 2020-11-05 | $92.00K derived: sum of 2 quarters · filed 2021-11-04 | $127.00K 10-Q · filed 2021-11-04 | $126.46K 10-Q · filed 2020-11-05 | -$89.88K derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $66.00K 10-Q · filed 2021-08-05 | $66.49K 10-Q · filed 2020-08-11 | $100.00K 10-Q · filed 2021-08-05 | $100.44K 10-Q · filed 2020-08-11 | -$115.88K derived: sum of 3 quarters · filed 2021-08-05 | -$24.35K derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $34.00K 10-Q · filed 2021-05-06 | $33.95K 10-Q · filed 2020-05-07 | -$181.88K derived: sum of 2 quarters · filed 2021-05-06 | -$90.35K derived: sum of 3 quarters · filed 2021-05-06 | -$78.17K derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | -$215.88K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$124.35K derived: sum of 2 quarters · filed 2021-02-25 | -$112.17K derived: sum of 3 quarters · filed 2021-02-25 | $63.23K 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $91.53K 10-Q · filed 2020-11-05 | $103.71K derived: sum of 2 quarters · filed 2020-11-05 | $279.11K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $12.18K 10-Q · filed 2020-08-11 | $93.05K 10-Q · filed 2019-08-08 | $25.83K 10-Q · filed 2020-08-11 | $187.57K 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $13.65K 10-Q · filed 2020-05-07 | $94.53K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |